Submit Manuscript  

Article Details

New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention

[ Vol. 19 , Issue. 16 ]


Patrycjusz Kolodziejczyk, Anna Gromotowicz-Poplawska, Michal Aleksiejczuk, Ewa Chabielska, Piotr Tutka and Wojciech Miltyk*   Pages 1968 - 1979 ( 12 )


Aldosterone, the main mineralocorticoid hormone, plays a crucial role in the regulation of electrolyte homeostasis and blood pressure. Although this role is undoubtedly important, it is not a hormonal action that attracts the most attention. Aldosterone seems to be very important as a local messenger in the pathology of cardiovascular diseases (CVD). In the last few years, the attention was focused on the correlation between raised aldosterone level and increased risk of cardiovascular events. It has been demonstrated that aldosterone contributes to fibrosis, inflammation, endothelial dysfunction, fibrinolytic disorders, and oxidative stress leading to CVD development and progression. It used to be thought that the effects of aldosterone are mediated via classic nuclear receptors – mineralocorticoid receptors (MRs). Now we know that the mechanism of aldosterone action in the cardiovascular system (CVS) is much more complex since experimental and clinical studies indicate that MR blockade may be not sufficient to abolish aldosterone-induced harmful effects in CVS. Thus, the involvement of some other than MR, receptors, and factors is suggested. Moreover, in addition to the generally known genomic action of aldosterone, which involves MR activation, the nongenomic pathways are postulated in the mode of hormone action. More and more attention is focused on the membrane-coupled receptors, which mediate the rapid effects of aldosterone and have been already confirmed in different cells and tissues of CVS. Therefore, this brief review summarizes recent findings about new sides of aldosterone action in CVS that could be potential targets for therapeutic intervention.


Aldosterone, genomic, nongenomic, mineralocorticoid receptor, glucocorticoid receptor, angiotensin II receptor type 1, G protein-coupled estrogen receptor.


University of Rzeszów - Department of Experimental and Clinical Pharmacology Rzeszow, Medical University of Bialystok - Department of Biopharmacy Bialystok, Medical University of Bialystok - Department of Biopharmacy Bialystok, Medical University of Bialystok - Department of Biopharmacy Bialystok, University of New South Wales - National Drug and Alcohol Research Centre Sydney, Medical University in Bialystok - Department of Pharmaceutical Analysis Bialystok

Read Full-Text article